Exit Options for John Hancock Bond and Corporate Finance Group: Hanover Communications In... - 28 Strategic Investors

View x

News About Pharmaceuticals, Biotechnology & Life Sciences

Filters

Takeda Completes Sale of Select OTC and Non-Core Assets to Acino

Synedgen Receives $2.6 Million in Private Financing For Wound Care Portfolio

Novo Seeds portfolio company NorthSea Therapeutics raises US40m in Series B financing

Merck to buy Peloton Therapeutics

Catalent to acquire Paragon Bioservices

Advarra acquires Quorum

Charles River Laboratories acquires Citoxlab

H.I.G. Capital acquires Taconic Biosciences

InterMed acquires Horizon CSA

Tilray Inc acquires Natura Naturals

Kashiv Pharma to buy Adello Biologics LLC

10x Genomics acquires Spatial Transcriptomics

LGC acquires SeraCare

NeoGenomics to buy Genoptix

Geritrex acquires Unipack

Revolution Medicines acquires Warp Drive Bio

Nautic Partners buys Mikart Inc

Thompson Street Capital to buy LifeSpan Biosciences

Vantage Specialty Chemicals Holdings buys Amarna

Tower Three Partners to buy Nurse Assist

1 2 3 4 5

Why should I add a proposition?

  • Find counterparties that match your capital requirement or investment criteria
  • Get verified, vetted and analyst-picked introductions to relevant propositions
  • Generate new relationships
  • Add Proposition

Aurigin Updates

© Copyright 2023 AURIGIN, All rights reserved.

Securities are offered through Finalis Securities LLC, member of FINRA / SIPC. Aurigin is not a registered broker-dealer, and Finalis Securities LLC and Aurigin are separate, unaffiliated entities.

www.aurigininc.com is a website operated by Aurigin Inc., a privately held Delaware corporation. Aurigin provides deal origination services. Other services, such as securities-related transactions, are offered separately by Sohil Poojara in their capacity as registered representatives of Finalis Securities LLC, member of FINRA/SIPC.